{"filings":[{"id":78284,"accession_number":"0001193125-26-222923","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-05-14T12:45:19+00:00","items":["1.01","1.02","2.01","5.01","3.01","3.03","5.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Biogen completes $5.3B acquisition of Apellis; stockholders get $41 cash + CVR up to $4","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 105.7M shares (~82.4%); merger effective May 14, 2026.","Consideration per share: $41 cash plus CVR worth up to $4 based on SYFOVRE sales milestones.","CVR milestones: $2 if SYFOVRE net sales ≥$1.5B by 2030; $2 if ≥$2B by 2031 (or $4 if second met first).","Apellis common stock delisted from Nasdaq; intends to terminate SEC reporting obligations.","Board resigned; Michael Dambach (Biogen designee) becomes sole director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93160,"accession_number":"0001193125-26-202504","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis amends executive severance plan to accelerate vesting upon change of control in Biogen merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation committee approved amendment to Executive Separation Benefits Plan on April 28, 2026, in connection with Biogen merger.","Unvested converted options and RSU awards will accelerate upon termination without cause or for good reason after closing.","'Good Reason' definition modified for C-Level Officers to include changes in scope due to becoming a subsidiary.","Amendment effective upon closing of the merger; applies to each named executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104556,"accession_number":"0001193125-26-134916","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).","CVRs entitle holders to up to $4.00/share based on SYFOVRE net sales milestones ($1.5B or $2B).","Tender offer to commence for all shares; no stockholder vote required; minimum condition >50% tendered.","Support stockholders owning ~14% of shares agree to tender; termination fee $205M under certain conditions.","Apellis board unanimously recommends; deal expected to close by Sept 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104555,"accession_number":"0001193125-26-084156","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis adds Dr. Mikael Dolsten as independent Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.","Dolsten deemed independent under Nasdaq rules; no committee appointments at this time.","Received initial equity grant: option with $300,000 Black-Scholes value (3-year vest) and RSUs worth $300,000 (1-year cliff vest).","Standard indemnification agreement in place; no family relationships or transactions with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104554,"accession_number":"0001193125-26-010540","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary 2025 U.S. net product revenues of $689M; cash $466M; SYFOVRE injections up 17%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.","SYFOVRE total injection demand grew 17% YoY; ~60% market share in geographic atrophy; prefilled syringe submission planned 1H 2026.","EMPAVELI C3G/IC-MPGN launch: 267 patient start forms in 2025, >5% market penetration; 95% payer coverage.","Cash and cash equivalents ~$466M at Dec 31, 2025; company expects to fund operations to profitability.","Pivotal trials initiated for EMPAVELI in FSGS and DGF; IND for APL-9099 (FcRn) planned 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137438,"accession_number":"0001193125-25-153429","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.","Royalty obligations under Collaboration Agreement reduced by 90% from closing, subject to cap of 1.45x payments made.","Sixth Street lenders consent to deal; Apellis extends prepayment premium periods on credit facility by one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154756,"accession_number":"0001193125-25-134886","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis shareholders elect three Class II directors and ratify Deloitte as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.","Ratified Deloitte & Touche as independent auditor for FY2025 with 103.9M for, 54.6K against, 116.2K abstain.","Approved non-binding advisory vote on named executive officer compensation: 75.9M for, 4.17M against, 59.9K abstain.","Recommended future say-on-pay votes every year (79.86M for 1-year); company will hold annual advisory votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154755,"accession_number":"0001193125-25-086304","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.","Appointed to Audit Committee effective May 1, 2025; determined independent under Nasdaq rules.","Received option for 28,195 shares at $18.20 (3-year vest) and 16,483 RSUs (1-year vest).","Wheeler is former CEO of Momenta Pharmaceuticals (acquired by J&J) and current CEO of Headwaters Biotech Advisors.","No arrangements or family relationships with existing directors or executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173264,"accession_number":"0001193125-25-005052","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.","Cash and equivalents $410M as of Dec 31, 2024, up from $351M a year earlier.","sNDA for C3G/IC-MPGN expected early 2025; 2H 2025 launch if approved. Phase 3 FSGS and DGF studies planned 2H 2025.","COO Adam Townsend to depart Feb 21, 2025; David Acheson named EVP of commercial.","Keli Walbert elected to Board; ex-U.S. workforce reduced by ~40 employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206780,"accession_number":"0001193125-24-196465","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.","Key secondary endpoints met: composite renal endpoint and ≥50% proteinuria reduction.","Favorable safety profile; no meningitis or serious infections from encapsulated bacteria.","All VALIANT completers enrolled in long-term extension study VALE.","Apellis to file sNDA with FDA in early 2025; Sobi to submit EMA application in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224030,"accession_number":"0001193125-24-155179","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis stockholders elect directors, ratify auditor, approve executive pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paul Fonteyne elected with 98,837,712 votes for and 5,320,270 withheld; Stephanie Monaghan O'Brien elected with 80,481,023 for and 23,672,152 withheld.","Ratification of Deloitte & Touche as auditor passed with 109,564,727 for, 56,762 against, and 42,951 abstain.","Advisory vote on executive compensation approved with 93,573,357 for, 10,540,010 against, and 44,708 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224029,"accession_number":"0001193125-24-137743","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Apellis closes $375M senior secured term loan; buys out SFJ Pharmaceuticals liability","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Apellis entered $475M credit facility with Sixth Street; initial draw $375M; maturity May 2030 at SOFR+5.75% (1% floor).","Proceeds used to buy out remaining SFJ Pharmaceuticals liability for ~$326M, eliminating $366M in future payments.","Optional $100M draw available if SYFOVRE trailing 3-month sales ≥ $180M and $50M cash minimum met.","Credit facility secured by substantially all assets including IP; liquidity covenant if market cap < $3B.","No scheduled amortization; principal due at maturity; prepayment permitted with premium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243393,"accession_number":"0001193125-24-047073","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.","SYFOVRE: over 160,000 commercial and sample doses distributed in 2023; Q4 net revenue $114.3M.","Net loss $528.6M for 2023 (vs $652.2M in 2022); cash $351.2M as of Dec 31, 2023.","Entered agreements to unwind ~80% of capped calls on convertible notes due 2026; expects ~$100M proceeds.","G&A expenses rose to $500.8M in 2023 (vs $277.2M in 2022) on SYFOVRE commercial launch costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":396591000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243392,"accession_number":"0001193125-24-011699","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.","Townsend's background includes senior leadership roles at Biogen, including SVP of Corporate Development.","No family relationships with directors or executive officers, and no reportable transactions.","Appointment effective January 16, 2024, by the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243391,"accession_number":"0001193125-24-003998","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.","Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.","SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.","EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":396591000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260782,"accession_number":"0001193125-23-294892","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis receives negative trend vote on EU MAA for pegcetacoplan; expects CHMP negative opinion in Jan 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.","Apellis expects CHMP to adopt negative opinion at Jan 22-25, 2024 meeting.","Company plans to appeal and seek re-examination of the opinion.","Pegcetacoplan is for GA secondary to age-related macular degeneration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260781,"accession_number":"0001193125-23-286826","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.","Estimated rate of retinal vasculitis remains rare at 0.01% per injection, based on over 120,000 injections administered as of Nov 18, 2023.","Label update pursued in collaboration with the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260780,"accession_number":"0001193125-23-267745","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.","Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.","Cowen will receive up to 3.0% commission on gross proceeds from sales.","ATM offering made under existing shelf registration statement (File No. 333-269899)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260779,"accession_number":"0001193125-23-251073","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.","More than 100,000 vials (commercial+sample) distributed to date; ~37,000 commercial and 10,000 samples in Q3.","Permanent J-code effective Oct 1; >95% of Medicare payers now covering SYFOVRE.","GALE extension study shows up to 45% reduction in nonsubfoveal GA lesion growth at Months 24-30 vs projected sham.","Estimated retinal vasculitis rate remains rare at 0.01% per injection; 10 confirmed events, 2 suspected."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":250214000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278058,"accession_number":"0001193125-23-222977","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Apellis announces 25% workforce reduction, expects up to $300M cost savings through 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduce workforce by ~225 employees (~25% of total); substantially complete in Q3 2023.","Cost savings of up to $300M through 2024, including $70M+ from workforce reduction and up to $230M from external expenses.","Focus on SYFOVRE U.S. launch and preparation for ex-U.S. launches; reduce EMPAVELI expenses.","Prioritize retina and CNS research; deprioritize siRNA with systemic pegcetacoplan, APL-1030, APL-2006.","Expect $9M-$11M cash costs for restructuring; update on cash runway in Q3 2023 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278057,"accession_number":"0001193125-23-218062","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis updates on 8 retinal vasculitis events with SYFOVRE; recommends switching to 18-gauge filter needle","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 100,000 SYFOVRE vials distributed; 8 confirmed retinal vasculitis events (5 occlusive, 3 non-occlusive) as of June 20.","Last confirmed event on June 20; over 32,000 vials distributed since then with no new confirmed events.","One additional occlusive event in May reported after July 29; all events occurred after first injection.","Company recommends discontinuing use of 19-gauge filter needle kits; now exclusively distributing 18-gauge filter needle kits.","Patient outcomes: 1 stable, 2 near baseline, 2 severe vision impairment, 3 pending; two suspected events also reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278056,"accession_number":"0001193125-23-198578","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).","Net loss of $122.0M improved from $156.0M loss in Q2 2022; cash $616.3M.","SYFOVRE reduced nonsubfoveal GA lesion growth up to 45% at Months 24-30 in GALE extension.","Investigation of rare retinal vasculitis events found no drug product or manufacturing issues.","R&D expenses $95.7M, G&A $111.4M; company funded into Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":139814000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278055,"accession_number":"0001193125-23-188117","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Apellis reports 6 retinal vasculitis events after SYFOVRE; rate ~0.01% per injection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six retinal vasculitis events observed after first SYFOVRE injection, 7-13 days post-dose; no specific lot implicated.","Estimated event rate ~1 per 10,000 injections (0.01%); approximately 60,000 vials distributed since FDA approval.","Two events confirmed occlusive, one non-occlusive, three undetermined; etiology unclear, outcomes evolving.","Zero retinal vasculitis events in clinical trials (>23,000 injections); FDA notified, no action planned at this time.","Company investigating with ASRS ReST Committee and external specialists; will update as new info emerges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296128,"accession_number":"0001193125-23-158943","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis stockholders re-elect Gerald Chan and Cedric Francois as Class III directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gerald Chan received 82,568,712 votes for and 19,616,976 withheld (5,095,730 broker non-votes).","Cedric Francois received 101,552,924 votes for and 632,764 withheld (5,095,730 broker non-votes).","Stockholders ratified Deloitte & Touche as auditor for FY2023 (107,213,813 for, 39,783 against).","Advisory vote on named executive officer compensation passed with 94,979,579 for, 6,659,652 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316643,"accession_number":"0001193125-23-071396","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA extends PDUFA goal date for Apellis' EMPAVELI Injector sNDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Apellis on March 14, 2023 that labeling review is ongoing and the March 15, 2023 PDUFA goal date will be missed.","New PDUFA goal date for the EMPAVELI Injector (for PNH self-administration) has not yet been determined.","EMPAVELI (pegcetacoplan) is currently approved for adults with paroxysmal nocturnal hemoglobinuria.","The injector is an on-body device designed to enhance self-administration of EMPAVELI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316642,"accession_number":"0001193125-23-047759","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apellis prices $350M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,174,603 shares at $63.00/share and pre-funded warrants for 2,380,956 shares at $62.9999/warrant.","Total gross proceeds ~$350M; net proceeds ~$333M (or ~$383M if underwriters' option exercised).","Underwriters granted 30-day option to purchase up to 833,333 additional shares.","Expected closing February 27, 2023; net proceeds to fund operations into Q1 2025.","J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316641,"accession_number":"0001193125-23-004423","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["5.02","2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.","Submitted New Drug Application to US FDA and Marketing Authorization Application to EMA for pegcetacoplan.","Appointed Dr. Caroline Baumal as Chief Medical Officer effective Q1 2023.","Completed enrollment in Phase 2 ALS study; progressed late-stage pipeline with partner Sobi.","Deployed ~100 field-based employees mid-2022 for US commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316640,"accession_number":"0001193125-23-001962","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.","Caroline Baumal, M.D., appointed CMO effective Jan 3, 2023, succeeding Dr. Grossi.","Dr. Grossi will continue at Apellis through Feb 28, 2023 to assist transition and pegcetacoplan launch preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352343,"accession_number":"0001193125-22-228145","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis reports 24-month Phase 3 data: pegcetacoplan shows increasing efficacy in GA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 24 months, monthly pegcetacoplan reduced GA lesion growth 19% in DERBY (p=0.0004) and 22% in OAKS (p<0.0001) vs sham.","Between months 18-24, treatment effect accelerated: DERBY monthly 36% (p<0.0001), OAKS monthly 24% (p=0.0080) reduction.","Safety profile consistent; infectious endophthalmitis rate 0.034% per injection, no occlusive vasculitis or retinitis over 24 months.","US PDUFA target action date Nov 26, 2022; EU marketing authorization application planned by end of 2022.","Key secondary visual function endpoints showed no clinically meaningful difference at 24 months, attributed to endpoint limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352342,"accession_number":"0001193125-22-210079","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Apellis exchanges $22.5M convertible notes for shares; prior $75.6M exchange closed Aug 1","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Signed exchange agreements on July 28 to convert $22.5M in 3.5% convertible notes due 2026 into common stock.","Consideration includes 456,128 shares fixed plus additional shares based on volume-weighted average price over 3 trading days.","Prior exchange of $75.6M principal closed Aug 1, issuing 2,334,014 shares—combined ~$98.1M of notes converted.","Shares issued in private placement to QIBs and accredited investors; no registration under Securities Act.","No cash interest paid on exchanged notes; holders waived accrued interest and conversion rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352341,"accession_number":"0001193125-22-202617","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Apellis exchanges $75.6M of convertible notes for common stock shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$65.9M principal for 2,036,886 shares; ~$9.7M for 195,809 shares plus additional based on VWAP.","Transactions expected to close August 1, 2022, subject to customary closing conditions.","Shares issued to QIBs and institutional accredited investors under Section 4(a)(2) exemption.","Debt reduction strengthens balance sheet but dilutes existing shareholders by ~2.2M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352340,"accession_number":"0001193125-22-196599","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA grants Priority Review for Apellis' pegcetacoplan to treat geographic atrophy; PDUFA Nov 26, 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted and granted Priority Review for intravitreal pegcetacoplan NDA for geographic atrophy (GA).","PDUFA target action date set for November 26, 2022; no advisory committee meeting planned.","Apellis plans to submit marketing authorization application to European Medicines Agency in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369878,"accession_number":"0001193125-22-166256","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apellis shareholders re-elect Dunlop and Machiels as directors, ratify auditor and approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["A. Sinclair Dunlop re-elected with 67,011,560 for vs 19,188,626 against, 8,818,334 broker non-votes.","Alec Machiels re-elected with 63,755,893 for vs 22,444,293 against, 8,818,334 broker non-votes.","Ratification of Deloitte & Touche as auditor for FY2022: 75,696,485 for, 19,169,304 against.","Advisory vote on executive compensation approved: 84,569,740 for, 1,617,364 against, 13,081 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389005,"accession_number":"0001193125-22-084200","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apellis prices public offering of 7.4M shares at $47/sh, raising $350M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,446,809 shares at $47.00 per share; gross proceeds of $350 million.","Net proceeds estimated at $330.2 million ($379.8 million if underwriters' option fully exercised).","Offering expected to close March 28, 2022; underwriters have 30-day option for 1,117,021 additional shares.","J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389004,"accession_number":"0001193125-22-077217","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis reports positive 18-month Phase 3 data for pegcetacoplan in GA; NDA planned Q2 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OAKS GA: monthly pegcetacoplan reduced lesion growth 22% (p<0.0001); every-other-month 16% (p=0.0018) at month 18.","DERBY GA: monthly reduction 13% (p=0.0254); every-other-month 12% (p=0.0332); effects improved vs months 0-6.","Combined: monthly reduction improved from 13% (months 0-6) to 21% (months 12-18); every-other-month from 12% to 17%.","Safety: endophthalmitis rate 0.044% per injection; intraocular inflammation 0.23%; no retinal vasculitis or vein occlusion.","Company plans to submit NDA to FDA for intravitreal pegcetacoplan in GA in Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389003,"accession_number":"0001193125-22-013866","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Apellis enters $300M at-the-market equity offering with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Apellis may sell up to $300M common stock in at-the-market offerings through Jefferies LLC.","Jefferies receives commission of up to 3% of gross proceeds for acting as sales agent.","Prior $150M equity distribution agreement with Citigroup and Jefferies terminated.","Shares sold under existing automatic shelf registration statement effective Jan 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389002,"accession_number":"0001193125-22-005103","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).","Over 125 start forms submitted; >95% patient compliance; zero meningococcal infections.","More than 75% of new EMPAVELI starts are switches from competitor Ultomiris."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":66563000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406932,"accession_number":"0001193125-21-331994","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-11-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apellis Pharmaceuticals prices $350M public offering of 8.75M shares at $40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Apellis priced public offering of 8.75M shares at $40.00/share for gross proceeds of $350M.","Underwriters have 30-day option to purchase up to 1.3125M additional shares at the same price less discounts.","Estimated net proceeds of ~$330.2M, or ~$379.8M if underwriters fully exercise option.","Offering expected to close Nov. 18, 2021; J.P. Morgan, Goldman Sachs, Evercore are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425935,"accession_number":"0001193125-21-268814","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apellis announces mixed Phase 3 GA trial results; OAKS met primary endpoint, DERBY missed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OAKS trial met primary endpoint: monthly pegcetacoplan reduced GA lesion growth by 22% (p=0.0003), every-other-month by 16% (p=0.0052) vs sham at 12 months.","DERBY trial missed primary endpoint: monthly reduced growth by 12% (p=0.0528), every-other-month by 11% (p=0.0750) vs sham.","Prespecified combined analysis: monthly reduced growth by 17% (p<0.0001), every-other-month by 14% (p=0.0012) vs sham at 12 months.","Greater effect in extrafoveal lesions: combined analysis showed 26% (monthly) and 23% (every-other-month) reduction vs sham (p<0.001).","Company plans to submit NDA to FDA in H1 2022 and MAA in Europe; well-tolerated with low rates of endophthalmitis and intraocular inflammation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425934,"accession_number":"0001193125-21-259951","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis appoints Jim Chopas as VP, Corporate Controller and CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Chopas named VP, Corporate Controller and principal accounting officer, effective August 30, 2021.","Annual base salary of $315,000; target bonus 30% of base; one-time sign-on bonus of $50,000.","Granted option for 21,750 shares and RSU for 7,600 shares, both vesting over four years.","Previously served as VP, principal financial and accounting officer and treasurer at Radius Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425933,"accession_number":"0001193125-21-251478","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apellis principal accounting officer Nicole Perry to depart Aug 30, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicole Perry will transition from principal accounting officer role effective August 30, 2021.","No successor or interim replacement has been announced.","Filing does not specify whether Perry will remain with the company in another capacity.","Reason for the departure is not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425932,"accession_number":"0001193125-21-223659","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apellis closes exchange of $201.1M convertible notes for 5.99M common shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $201.1M principal of 3.500% Convertible Senior Notes due 2026 for 5,992,217 common shares.","After exchange, approximately $192.7M principal amount of Notes remain outstanding with third parties.","Transaction closed on July 23, 2021; shares issued are unregistered and restricted.","Privately negotiated exchange reduces debt and dilutes existing equity by ~3% based on prior share count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425931,"accession_number":"0001193125-21-210295","cik":1492422,"company_name":"Apellis Pharmaceuticals, Inc.","ticker":"APLS","form_type":"8-K","filed_at":"2021-07-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Apellis exchanges $198.6M in convertible notes for common stock; closing July 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreed to exchange ~$198.6M principal of 3.500% Convertible Senior Notes due 2026 for shares.","Fixed issuance of 4,530,431 shares (22.8065 per $1,000 principal) plus additional variable shares tied to VWAP.","Exchange expected to close July 23, 2021, subject to customary conditions.","Shares issued in private placement to QIBs and institutional accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5252710000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}